Uncovering Ibogaine: The Deborah Mash Interview
Historical & modern Primary source high
⚠ Contains fatality data
AI-extracted · unverified · confirm at source
First-person account of FDA Phase I trial launch, noribogaine discovery, coca-ethylene backstory, neurotoxicity debate rebuttal, and funding barriers to ibogaine clinical development
Dosing: 2 mg/kg increments in dose-escalation design up to 14–15 mg/kg target; Mash states underground doses 'way too high' and could be cut by half (oral)
Contraindications: Pre-existing cardiac disease (woman with 'very sick heart' cited as contraindication violation in Baumann death), Unsupervised administration outside medical settings, Unknown source material (purity/identity of ibogaine unverifiable outside clinical supply)